Abstract:Background: Pakistan has a high hepatitis burden for both hepatitis C virus (HCV) and hepatitis B virus (HBV). To achieve World Health Organization (WHO) 2030 targets for hepatitis elimination, there is a need to constitute progress in the country, find the barriers and strategies for HCV elimination, and take actions to address the gaps. Methods: We collected data from (1) WHO estimates in 2020, (2) midterm review questionnaire of the WHO regional action plan, and (3) WHO estimates on immunization. We analyzed these data to inform (1) the burden defined as prevalence and mortality and (2) response in 3 thematic areas: governance, policy, and finance; strategic information; and service delivery. Results: The prevalence of hepatitis B in the general population is 1.6% with 12 000 deaths/year. The prevalence of hepatitis C in the general population is 7.5% with 19 000 deaths and 545 000 new cases (incidence)/year. The selected indicators to monitor progress on viral hepatitis in Pakistan were governance and financing, policies and guidelines, and strategic information. The overall governance indicators are good with a focal point, a national hepatitis strategy, an operational plan, strategy for price reduction, and involvement of civil society but the costed action plan and the advocacy strategy are missing. The indicators on policies and guidelines are also adequately addressed. The hepatitis B and C testing and treatment guidelines are available, there is a policy to screen all blood donations, and there is an injection safety policy, but the policy for timely hepatitis B vaccine birth dose and hepatitis B vaccination for the vulnerable is missing. Both indicators regarding strategic information, that is measures of key hepatitis indicators and regular data review, are missing. The status of 5 key interventions in Pakistan show that the hepatitis B vaccination coverage is 74% and only 3% of newborn children are given the hepatitis B vaccine birth dose. Only 22% of HCV cases have been diagnosed and 2% have received treatment. Treatment response is 96%. Same-day testing and treatment of hepatitis C reduced the overall dropout rate and improved the cascade of care. Decentralization and task shifting are important tools to improve service delivery and reach communities. Finances to implement hepatitis elimination is a major barrier. Conclusions: Pakistan has the highest hepatitis disease burden. With the current pace, hepatitis elimination appears impossible. Introduction of the birth dose of hepatitis B vaccine and improving access and affordability of testing can improve the testing and treatment numbers. Finances need to be mobilized from within the country and outside to support disease elimination.

Correction: Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis

Erratum: Clinical trials landscape in lower middle-income country (Pakistan) - CORRIGENDUM

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Correction: Increase in HIV viral suppression in KwaZulu-Natal, South Africa: Community-based cross sectional surveys 2018 and 2013. What remains to be done?

Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan

Corrigendum to ‘therapeutic HNF4A Mrna Attenuates Liver Fibrosis in a Preclinical Model’ [J Hepatol (2021) 1420-1433]

Author Correction: Prevalence and Characteristics of Hypoxic Hepatitis in the Largest Single-Centre Cohort of Avian Influenza A(H7N9) Virus-Infected Patients with Severe Liver Impairment in the Intensive Care Unit

Correction To: Basiliximab Versus Rabbit Antithymocyte Globulin As Induction Therapy for Living-Related Renal Transplantation: a Single-Center Experience

Erratum to: Breast implant-associated Epstein-Barr virus-positive large B-cell lymphomas: a report of three cases

Correction: What gaps remain in the HIV cascade of care? Results of a population-based survey in Nsanje District, Malawi

Correction: The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

Corrigendum: Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis

Correction: Assessing the consistency of iPSC and animal models in cystic fibrosis modelling: A meta-analysis

Corrigendum To: "pkcα/zfp64/csf1 Axis Resets the Tumor Microenvironment and Fuels Anti-Pd1 Resistance in Hepatocellular Carcinoma" [J Hepatol 77 (2022) 163-176].

Correction: Understanding the quality of life of people living with HIV in rural and urban areas in Indonesia

Erratum: Thadi A.; et al. Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. Vaccines 2018, 6, 54

Corrigendum: A matter of life or death: Productively infected and bystander CD4 T Cells in early HIV infection

Correction: COVID-19 health awareness among the United Arab Emirates population

Barriers and Strategies for Hepatitis B and C Elimination in Pakistan

Corrigendum to: Older adults’ experiences of a community wellness program (Connect 60+) that focused on physical activity and social connections: a qualitative exploratory study